Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
An integrated prime editing system for pathogenic cystic fibrosis transmembrane conductance regulator allele correction in human cells
EF 2022-23
Résumé
Cystic fibrosis (CF) is the most common fatal inherited disease, affecting approximately 90,000 people globally, with more than 4,300 in Canada. It is a multi-organ disease, but in the lungs, where the effects are most devastating, a build-up of thick mucus causes severe respiratory problems. CF is progressive, meaning it worsens over time, and lung damage will eventually lead to premature death. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that encodes for the CFTR protein. The most common CF-causing mutation that is found in approximately 90% of CF patients is called CFTR-F508del, where there is an absence of the protein on the cell surface. At present, there is no cure for CF, and while currently approved drugs treat people with CFTR-F508del, there are considerable variations in drug responses and current drugs are not effective for all CF mutations. Therefore, permanent correction of the disease-causing F508 deletion mutation is needed, and we propose that this can be potentially achieved by utilizing the recently developed genome editing tool called prime editing. Prime editing directly writes new genetic information into a specified DNA site, and compared to other gene-editing technologies, it offers an unusual combination of versatility, specificity, and precision. Here, we will engineer an integrated prime editing system to enhance the efficiency of permanent and specific correction of the CFTR-F508del mutation in human CF lung epithelial cells and in three-dimensional lung tissue cultures grown from stem cells. We hope that this study will expand prime editing’s capabilities and demonstrate its application for gene therapy to treat genetic diseases.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486540
Name
Chang Yoon Soo
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
An integrated prime editing system for pathogenic cystic fibrosis transmembrane conductance regulator allele correction in human cells
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clustered Regularly Interspaced Short Palindromic Repeats; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Gene Therapy; Genome Editing; Lungs; Organoids; Precision Medicine; Prime Editing; Stem Cells
Abstract
Cystic fibrosis (CF) is the most common fatal inherited disease, affecting approximately 90,000 people globally, with more than 4,300 in Canada. It is a multi-organ disease, but in the lungs, where the effects are most devastating, a build-up of thick mucus causes severe respiratory problems. CF is progressive, meaning it worsens over time, and lung damage will eventually lead to premature death. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that encodes for the CFTR protein. The most common CF-causing mutation that is found in approximately 90% of CF patients is called CFTR-F508del, where there is an absence of the protein on the cell surface. At present, there is no cure for CF, and while currently approved drugs treat people with CFTR-F508del, there are considerable variations in drug responses and current drugs are not effective for all CF mutations. Therefore, permanent correction of the disease-causing F508 deletion mutation is needed, and we propose that this can be potentially achieved by utilizing the recently developed genome editing tool called prime editing. Prime editing directly writes new genetic information into a specified DNA site, and compared to other gene-editing technologies, it offers an unusual combination of versatility, specificity, and precision. Here, we will engineer an integrated prime editing system to enhance the efficiency of permanent and specific correction of the CFTR-F508del mutation in human CF lung epithelial cells and in three-dimensional lung tissue cultures grown from stem cells. We hope that this study will expand prime editing’s capabilities and demonstrate its application for gene therapy to treat genetic diseases.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chang, Yoon Soo
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~